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Abstract
Purpose This exploratory analysis assessed and com-
pared patients’ treatment satisfaction with empagliflozin
plus metformin versus glimepiride plus metformin, using
data obtained from the Diabetes Treatment Satisfaction
Questionnaire, status version (DTSQs) collected in a ran-
domized, double-blind, double-dummy clinical trial.
Methods Observed values for DTSQs scale score and
each of its eight items were summarized by visit and
treatment arm. Changes from baseline in these scores were
analyzed using linear mixed models for repeated measures.
Results The baseline scale score and item scores were
comparable between empagliflozin plus metformin
(n = 765) and glimepiride plus metformin (n = 780).
Compared with baseline, patients reported significant
treatment satisfaction increases and significant decreases in
perceived hyperglycemia with both treatments at all visits.
Also, compared with baseline, a significant increase in
perceived frequency of hypoglycemia was observed in the
glimepiride treatment group at all visits. No statistically
significant treatment difference was observed in DTSQs
scale score and its items at week 104. The difference
between the treatment groups was significant and in favor
of empagliflozin from week 28 onward for perceived fre-
quency of hyperglycemia (P B 0.006) and perceived fre-
quency of hypoglycemia (P B 0.011).
Conclusions Despite positive trends in favor of empa-
gliflozin, there was no significant difference in DTSQs
scale score between empagliflozin and glimepiride at
104 weeks. However, when compared with glimepiride,
empagliflozin demonstrated significantly lower perceived
frequency of hyperglycemia and hypoglycemia at all visits
from week 28 onward. This finding is consistent with the
clinical results reported for the EMPA-REG H2H-SU trial.
Keywords Type 2 diabetes mellitus  Diabetes Treatment
Satisfaction Questionnaire  Empagliflozin  Glimepiride
Introduction
Diabetes is a disease with a large and increasing societal
cost due to the number of people affected worldwide and
its associated complications, such as increased risk of
cardiovascular disease, neuropathy, and eye complications.
In 2013, 382 million patients worldwide were estimated to
have diabetes, of which 46 % (175 million) were undiag-
nosed. The number of patients living with diabetes is
estimated to increase by 55 % (592 million) by 2035 [1].
The majority of patients with diabetes have type 2 diabetes
mellitus (T2DM), approximately 85–95 % in high-income
countries and even more in low- and middle-income
countries [1]. T2DM is characterized by insulin resistance
and a progressive decrease in the ability of the beta cells in
the pancreas to produce sufficient amounts of insulin to
control blood glucose.
Quality of life and patient-reported outcome (PRO)
measures are collected in clinical trials because they offer
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information from the patient perspective, which is beyond
the usual efficacy and safety profiles of a drug. PROs
measuring treatment satisfaction have an important place in
diabetes management because treatment satisfaction is
important to patients and because better treatment satis-
faction may have a positive impact on treatment adherence
and self-management behavior [2]. The Diabetes Treat-
ment Satisfaction Questionnaire, status version (DTSQs) is
a PRO instrument which, according to the World Health
Organization and the International Diabetes Federation, is
‘‘useful in assessing outcomes of diabetes’’ [3]. The DTSQs
has been used in several studies to measure treatment sat-
isfaction and has shown sensitivity to changes in treatments
[4].
When T2DM is diagnosed, clinical guidelines recom-
mend starting treatment with changes in lifestyle, such as
diet and exercise; however, as the disease progresses, there
remains a need for antidiabetic drugs. According to the
American Diabetes Association and the European Associ-
ation for the Study of Diabetes, first-line treatment for the
management of hyperglycemia in patients with T2DM
consists of changes in lifestyle plus metformin; second-line
treatment consists of changes in lifestyle plus metformin
and sulfonylurea [5]. Other new classes of antidiabetic
agents, such as sodium-dependent glucose cotransporter 2
(SGLT-2) inhibitors, have also been introduced to the
market; these treatments are now being considered to
determine treatment algorithms for hyperglycemia in
patients with T2DM.
The SGLT-2 is expressed in the renal proximal tubules
and accounts for 90 % of the total renal glucose reab-
sorption in healthy individuals [6, 7]. Empagliflozin is an
oral antidiabetic drug that selectively inhibits the SGLT-2
and increases urinary glucose excretion by blocking glu-
cose reabsorption by the kidney. Treatment with empagli-
flozin in phase three clinical trials resulted in clinically
meaningful reductions in glycated hemoglobin (HbA1c),
systolic blood pressure, and body weight. Empagliflozin
also demonstrated good overall safety and tolerability in
patients with T2DM and showed a low risk of hypo-
glycemia [8–11]. EMPA-REG H2H-SU was one of the
phase three clinical trials in which patients with T2DM
who had insufficient glycemic control despite taking met-
formin were randomized to either empagliflozin or glime-
piride as add-on treatment to metformin. Glimepiride is
widely used and available at a reasonable price in many
countries for treatment of type 2 diabetes as monotherapy
or add-on therapy to metformin when diet and physical
exercise and weight reduction alone are not adequate [12,
13].
The objective of this exploratory analysis was to assess
and compare patients’ treatment satisfaction with empa-
gliflozin plus metformin versus glimepiride plus metformin
using data obtained from the DTSQs collected in the
EMPA-REG H2H-SU trial.
Methods
Data for this study were obtained from the EMPA-REG
H2H-SU clinical trial. This trial is described in detail in
Riddersta˚le et al. [11] and is briefly summarized here. After
a two-week open-label, placebo run-in period, 1549 patients
with T2DM and insufficient glycemic control (HbA1c from
7.0 to 10 % and body mass index B45 kg/m2 at screening)
were randomly assigned to receive for 104 weeks either
empagliflozin 25 mg orally once a day (n = 769, of which
765 received treatment) or glimepiride 1–4 mg orally once a
day (n = 780) as an add-on therapy to their current treat-
ment of immediate-release metformin [11]. Randomization
was performed via an interactive voice response system in
23 countries (Argentina, Austria, Canada, Colombia, Czech
Republic, Finland, Hong Kong, India, Italy, Malaysia,
Mexico, Netherlands, Norway, Philippines, Portugal, South
Africa, Spain, Sweden, Switzerland, Taiwan, Thailand,
United Kingdom, USA), and study medication was dis-
pensed in a double-blind, double-dummy manner. The
metformin dose (unchanged for 12 weeks prior to random-
ization) was C1500 mg per day, or the maximum dose tol-
erated, or the maximum dose according to the local label.
The starting dose of glimepiride was 1 mg/day and then was
up-titrated 1 mg/day every 4 weeks during the first
12 weeks of the treatment period up to the maximum of
4 mg/day if fasting home blood glucose monitoring values
were [110 mg/dL. Up-titration could be withheld during
the first 12 weeks, or down-titration could occur after the
first 12 weeks if the patient was at increased risk of hypo-
glycemia. All patients enrolled in the study provided
informed consent. The trial was conducted according to the
principles of the Declaration of Helsinki and the Interna-
tional Conference on Harmonisation’s Harmonised Tripar-
tite Guideline for Good Clinical Practice [11].
The main objective of the trial was to investigate the
efficacy, safety, and tolerability of empagliflozin 25 mg
compared with glimepiride 1–4 mg. The primary endpoint
was the change from baseline in HbA1c after 104 weeks of
treatment. Key secondary endpoints were occurrence of
confirmed hypoglycemic adverse events (plasma glucose
B3.9 mmol/L or requiring assistance) and change from
baseline in body weight and systolic and diastolic blood
pressure after 104 weeks of treatment. The PRO measures
that were included in the trial were the EuroQol 5
Dimensions health questionnaire (3 levels) and the DTSQs,
and both were administered at baseline and weeks 8, 28,
52, 74, and 104. Healthcare resource utilization was also
collected throughout the trial.
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The DTSQs (available from www.healthpsychology
research.com), which is the status version of the ques-
tionnaire, has a total of eight items: six items assessing
treatment satisfaction (i.e., overall treatment satisfaction,
treatment convenience, treatment flexibility, satisfaction
with understanding of diabetes, willingness to continue
present treatment, and willingness to recommend present
treatment to others) and two items assessing perceived
frequency of unacceptably high blood glucose levels (hy-
perglycemia) and unacceptably low blood glucose levels
(hypoglycemia) [14, 15]. Patient responses to each DTSQs
treatment satisfaction item are reported on a 7-point Likert
scale, with 6 being very satisfied, very convenient, and very
flexible and 0 being very dissatisfied, etc. The DTSQs scale
score is calculated by summing the six individual treatment
satisfaction item scores; scale scores can range between 0
and 36, with higher scores indicating more satisfaction with
treatment. The DTSQs scale score was set to missing if any
of the six individual items were missing. The questions
assessing hyperglycemia and hypoglycemia are stand-alone
items and are treated separately from treatment satisfac-
tion. These two items also are reported on a 7-point Likert
scale between 6 and 0; for these two questions, lower
scores indicate fewer episodes of hyperglycemia or
hypoglycemia.
The analysis population for the DTSQs scale score,
perceived hyperglycemia, and perceived hypoglycemia
consisted of all patients in the full analysis set (i.e., all
randomized patients treated with at least one dose of the
study drug and with a baseline HbA1c measurement) with
a baseline and at least one postbaseline DTSQs measure-
ment (i.e., DTSQs scale score, perceived hyperglycemia,
perceived hypoglycemia).
The number and percentage of patients who completed
DTSQs assessments were reported for each scheduled visit.
Summary tables were created based on the observed values
by visit and treatment arm for DTSQs scale score and each
of the eight items assessed in the questionnaire. Changes
from baseline in DTSQs scale score and each of the eight
item scores were analyzed using linear mixed models for
repeated measures across postbaseline visits. The models
included treatment, visit, and interaction between treatment
and visit as fixed effects, regardless of their significance. A
random intercept for patients was also programmed into the
models to account for within-patient correlations. In addi-
tion, a pool of potential adjustment covariates was
reviewed for inclusion into each of the models using a
backward-selection process.
Continuous variables included baseline values of
DTSQs, age, body mass index, HbA1c, and systolic and
diastolic blood pressure; and categorical variables included
baseline values of estimated glomerular filtration rate
(eGFR), time since diagnosis, sex, race, country, prior
cardiovascular event, and cardiovascular risk predictors,
defined as yes/no, where ‘‘yes’’ meant the occurrence of at
least one of the following events: blood pressure (sys-
tolic/diastolic) [140/90 mmHg, or HbA1C level at base-
line C8.5, or eGFR at baseline B59, or a prior
cardiovascular event occurred. Due to the exploratory
nature of this analysis, variables with a P value B0.10,
rather than the usual 0.05, were selected for the final
adjusted models through the backward selection.
The same models were fitted for DTSQs scale score and
its individual items to ensure consistency and compara-
bility; different models were fitted for the stand-alone
perceived hyperglycemia and perceived hypoglycemia
items. Adjusted means by treatment and differences in
adjusted means were estimated at each visit, but the pri-
mary visit for the analyzed endpoints was 104 weeks. Due
to the exploratory nature of the analysis, no adjustment for
multiplicity was performed. A P value of 0.05 was used to
determine statistical significance.
Results
The EMPA-REG H2H-SU clinical trial’s results were
described in detail in Riddersta˚le et al. [11] and are briefly
summarized here. When compared to patients taking gli-
mepiride added to metformin, patients taking empagliflozin
added to metformin showed a sustained reduction in
HbA1c, significant at week 104 (adjusted mean difference
of -0.11 %, P = 0.0153 for superiority in favor of
empagliflozin; 95 % confidence interval [CI] -0.19 to
-0.02 %). A sustained and significant difference in body
weight and blood pressure, in favor of empagliflozin, was
also noted in all visits. Furthermore, significantly fewer
patients taking empagliflozin had confirmed hypoglycemic
adverse events than patients taking glimepiride within 104
weeks (relative risk ratio adjusted for baseline HbA1c
(\8.5 vs. C8.5 %) was 0.102 (95 % CI, 0.065–0.162).
Based on the adverse events with a frequency of at least
10 % in each treatment group, a higher percentage of the
following adverse events was observed in the glimepiride
treatment group than in the empagliflozin treatment group:
hyperglycemia (22 vs. 14 %) and hypertension (10 vs.
5 %). A higher percentage of one or more serious adverse
events (16 vs. 11 %) and of events consistent with genital
infections (12 vs. 2 %) was observed in empagliflozin than
in glimepiride. The percentage of events consistent with
urinary tract infection was similar between the treatment
groups (13 % in glimepiride vs. 14 % in empagliflozin).
The demographic and baseline characteristics were
comparable between the treatment groups (Table 1).
The completion rate for the DTSQs instrument was high,
and the rate was similar between the treatment arms;
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Table 1 Demographic and baseline characteristics for full analysis set population







Male 432 (56.5) 421 (54.0) 853 (55.2)
Female 333 (43.5) 359 (46.0) 692 (44.8)
Race [n (%)]
Asian 254 (33.2) 253 (32.4) 507 (32.8)
Black/African American 12 (1.6) 8 (1.0) 20 (1.3)
Other (i.e., American Indian/Alaska Native, Hawaiian/Pacific
Islander)
1 (0.1) 0 1 (0.1)
White 498 (65.1) 519 (66.5) 1017 (65.8)
Country [n (%)]
United States 43 (5.6) 51 (6.5) 94 (6.1)
Other 722 (94.4) 729 (93.5) 1451 (93.9)
Age group [years, n (%)]
\50 197 (25.8) 212 (27.2) 409 (26.5)
50–65 420 (54.9) 434 (55.6) 854 (55.3)
[65 148 (19.3) 134 (17.2) 282 (18.2)
Age [years, mean (SD)] 56.20 (10.30) 55.67 (10.44) 55.93 (10.37)
Baseline BMI [n (%)]
\25 131 (17.1) 112 (14.4) 243 (15.7)
25–30 289 (37.8) 309 (39.6) 598 (38.7)
[30 345 (45.1) 359 (46.0) 704 (45.6)
Baseline BMI [kg/m2, mean (SD)] 29.95 (5.28) 30.27 (5.30) 30.11 (5.29)
Baseline HbA1c [n (%)]
\7.5 250 (32.7) 281 (36.0) 531 (34.4)
7.5 to\8.5 334 (43.7) 308 (39.5) 642 (41.5)
8.5 to\9.5 138 (18.0) 146 (18.7) 284 (18.4)
C9.5 43 (5.6) 45 (5.8) 88 (5.7)
Baseline HbA1c [%, mean (SD)] 7.92 (0.81) 7.92 (0.86) 7.92 (0.84)
Baseline systolic blood pressure, seated [mmHg, mean (SD)] 133.42 (15.92) 133.54 (15.98) 133.48 (15.95)
Baseline diastolic blood pressure, seated [mmHg, mean (SD)] 79.54 (9.59) 79.38 (9.24) 79.46 (9.41)
Blood pressure [systolic/diastolic, mmHg, mean (SD)]
\120/\80 346 (45.2) 350 (44.9) 696 (45.1)
120–140/80–90 167 (21.8) 169 (21.7) 336 (21.7)
[140/[90 252 (33.0) 261 (33.5) 513 (33.2)
Baseline eGFR [n (%)]
C90 313 (40.9) 318 (40.8) 631 (40.8)
60 to\90 439 (57.4) 440 (56.4) 879 (56.9)
30 to\60 13 (1.7) 22 (2.8) 35 (2.3)
Baseline eGFR (MDRD) [mL/min/1.73 m2, mean (SD)] 87.94 (16.82) 88.11 (17.85) 88.02 (17.34)
Time since diagnosis of T2DM [years, n (%)]
B1 79 (10.3) 93 (11.9) 172 (11.1)
[1–5 341 (44.6) 336 (43.1) 677 (43.8)
[5–10 214 (28.0) 211 (27.1) 425 (27.5)
[10 131 (17.1) 140 (17.9) 271 (17.6)
Prior cardiovascular events [n (%)]
Yes 152 (19.9) 155 (19.9) 307 (19.9)
No 613 (80.1) 625 (80.1) 1238 (80.1)
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completion rates were 92 % or greater up to 52 weeks and
almost 92 % after 52 weeks (Table 2).
The baseline DTSQs scale score was comparable
between the treatment arms, with an unadjusted mean of 30
(out of a maximum of 36), indicating relatively high sat-
isfaction. The mean DTSQs scale score increased slowly
but steadily over time in both treatment arms and was
slightly larger for the empagliflozin arm than for the gli-
mepiride arm from week 52 onwards (Fig. 1a). The mean
perceived hyperglycemia score, which was low and similar
at baseline (mean, 2.5), decreased sharply for both arms at
week 8 and then remained almost constant for glimepiride,
while scores decreased further for empagliflozin (Fig. 1b).
The mean baseline score for perceived hypoglycemia was
0.76 for empagliflozin and 0.85 for glimepiride. The scores
fluctuated around the baseline mean for patients taking
empagliflozin, whereas scores increased in glimepiride
patients (Fig. 1c).
Table 3 presents adjusted mean scores at each post-
baseline visit and the corresponding treatment differences
in changes from baseline in DTSQs scale score and its
individual items. The covariates selected for the final
adjusted model for DTSQs total score and its individual
items were baseline DTSQs scale score, diastolic blood
pressure, and race. Within each treatment arm, significant
increases from baseline in treatment satisfaction were
observed for DTSQs scale score and its individual items at
all visits. Between the two treatment arms, no significant
differences in the adjusted mean change from baseline
were observed for DTSQs scale score and its individual
items at week 104, the primary time point in the study.
However, significant treatment differences in favor of
empagliflozin were observed at other endpoints, namely
weeks 52 and 78 for DTSQs scale score and treatment
recommendation, at week 52 for treatment flexibility, and
at week 78 for current treatment satisfaction and treatment
convenience (Table 3).
Table 4 presents results for perceived hyperglycemia
and hypoglycemia. The final adjusted model for perceived
hyperglycemia included baseline hyperglycemia score,
age, country, diastolic blood pressure, and time since
diagnosis. Significant decreases in perceived hyper-
glycemia were observed in each treatment group at all
visits. Patients treated with empagliflozin showed more
pronounced changes from baseline in perceived hyper-
glycemia than patients treated with glimepiride at all visits;
the difference between the treatment groups was significant
from week 28 onwards (Table 4). The final adjusted model
Table 1 continued






Cardiovascular risk predictor [n (%)]a
Yes 442 (57.8) 469 (60.1) 911 (59.0)
No 323 (42.2) 311 (39.9) 634 (41.0)
BMI body mass index, eGFR estimated glomerular filtration rate, HbA1c glycated hemoglobin, MDRD modification of diet in renal disease, SD
standard deviation, T2DM type 2 diabetes mellitus
a Defined as yes/no, where ‘‘yes’’ meant the occurrence of at least one of the following events: blood pressure (systolic/diastolic) [140/




Fig. 1 Unadjusted mean scores by time: empagliflozin 25 mg versus
glimepiride 1–4 mg. DTSQs diabetes treatment satisfaction question-
naire, status version
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for perceived hypoglycemia included baseline hypo-
glycemia score, age, body mass index, HbA1c, and dias-
tolic and systolic blood pressure. Compared to baseline, a
significant increase in perceived hypoglycemia was
observed in the glimepiride treatment group at all visits,
whereas patients treated with empagliflozin showed no
significant increase from baseline in perceived hypo-
glycemia at any visit. The difference between the treatment
groups was significant and in favor of empagliflozin from
week 28 onwards (Table 4).
Discussion
The objective of this study was to compare the treatment
satisfaction, as measured by DTSQs scores, between
patients taking empagliflozin 25 mg and glimepiride
1–4 mg as add-on therapy to current metformin treatment.
Overall patient satisfaction at baseline was relatively high
in both treatment groups. Nevertheless, patient satisfaction
still increased significantly during the study within each
treatment group. Despite a positive trend, the adjusted
mean change from baseline in overall satisfaction was not
significantly higher in the empagliflozin arm than in the
glimepiride arm at the final visit. Similar results were
observed for the individual items used to calculate the
overall treatment satisfaction. Significant differences in
changes in DTSQs scale score and some of its individual
items, in favor of empagliflozin, were observed at weeks 52
and 78. However, given the potential inconsistency of
findings throughout the observation period, the exploratory
nature of this analysis, and the multiple comparisons being
tested, the results should be viewed with caution.
Consistent with the analyses of the investigator-reported
data described in Riddersta˚le et al. [11] are the significant
treatment differences for perceived hyperglycemia and
hypoglycemia, in favor of empagliflozin, at all visits after
week 8. The difference in the perceived hyperglycemia
scores was due to a more pronounced improvement (i.e.,
reduction) in perceived hyperglycemia for empagliflozin
patients than for glimepiride patients. The significant
treatment difference in the perceived hypoglycemia scores
was due to an increase in perceived hypoglycemia for
glimepiride patients, while no negative trend was reported
by patients treated with empagliflozin.
Gelhorn et al. [16], using a conjoint analysis that
assessed patient preferences, showed that the most impor-
tant factors that determined patients’ preferences for oral
medication were the likelihood of hypoglycemic events;
weight change, especially for patients taking two or more
medications; the likelihood of gastrointestinal side effects
or nausea; and medication efficacy. Although empagli-
flozin patients showed significant improvements in per-
ceived frequency of hyperglycemia and hypoglycemia
when compared with glimepiride patients, the sustained
weight loss, the reduced number of confirmed hypo-
glycemic events, and the reduction observed in HbA1c
seen in the EMPA-REG H2H-SU study did not translate
into significant benefit in DTSQs scale score; therefore,
further investigation is required.
Our study has several limitations. The DTSQs was used
in a double-blind, double-dummy trial, and this design
feature may mask the effect of treatment on individual
items (i.e., treatment convenience, treatment flexibility,
and satisfaction with understanding diabetes) and conse-
quently may dilute potential effects on the scale score.
Also, a ceiling effect was observed in this population with
the DTSQs (i.e., patients who were already very satisfied at
baseline on some or all items of the DTSQs have little or
no room for improvement). There is a change version of
the DTSQ, the DTSQc, which may overcome such ceiling
effects [17, 18], but this was not used in the present study.
To determine the clinical significance of a PRO measure,
researchers try to derive the minimal clinically important
Table 2 DTSQs completion
rates
Time Empagliflozin 25 mg Glimepiride 1–4 mg Overall
All randomized analysis set (N) 765 780 1545
DTSQs analysis set [n (%)]a 718 (94 %) 742 (95 %) 1460 (94 %)
Completed DTSQs [n (%)]
Baseline 718 (100 %) 742 (100 %) 1460 (100 %)
Week 8 713 (99 %) 736 (99 %) 1449 (99 %)
Week 28 690 (96 %) 705 (95 %) 1395 (96 %)
Week 52 666 (93 %) 685 (92 %) 1351 (93 %)
Week 78 649 (90 %) 659 (89 %) 1308 (90 %)
Week 104 621 (86 %) 634 (85 %) 1255 (86 %)
DTSQs Diabetes Treatment Satisfaction Questionnaire, status version
a DTSQs analysis set is defined as all patients having a baseline glycated hemoglobin measurement, a
baseline DTSQs assessment, and at least one postbaseline DTSQs assessment
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Table 3 Mean baseline and adjusted mean change from baseline in DTSQs scale score and its individual items
Scale score time point Empagliflozin 25 mga Glimepiride 1–4 mga Treatment difference between empagliflozin
25 mg and glimepiride 1–4 mgb
DTSQs scale score
Baseline [mean (SD)] 30.6 (5.5) 30.4 (5.4)
Change from baselinec
Week 8 1.3 1.3 0.0 (-0.4, 0.4) [P = 0.9741]
Week 28 1.6 1.5 0.1 (-0.3, 0.5) [P = 0.5070]
Week 52 2.2 1.7 0.5 (0.1, 0.9) [P = 0.0144]
Week 78 2.1 1.7 0.4 (0.0, 0.8) [P = 0.0398]
Week 104 2.3 2.1 0.2 (-0.2, 0.6) [P = 0.2991]
Current treatment satisfaction score
Baseline [mean (SD)] 5.11 (1.16) 5.05 (1.16)
Change from baselinec
Week 8 0.28 0.25 0.03 (-0.05, 0.11) [P = 0.4840]
Week 28 0.36 0.29 0.07 (-0.01, 0.16) [P = 0.1037]
Week 52 0.39 0.32 0.08 (-0.01, 0.16) [P = 0.0823]
Week 78 0.43 0.33 0.10 (0.01, 0.18) [P = 0.0301]
Week 104 0.42 0.39 0.03 (-0.06, 0.12) [P = 0.5620]
Treatment convenience score
Baseline [mean (SD)] 5.06 (1.20) 5.05 (1.14)
Change from baselinec
Week 8 0.23 0.23 -0.00 (-0.09, 0.09) [P = 0.9840]
Week 28 0.24 0.23 0.02 (-0.08, 0.11) [P = 0.7230]
Week 52 0.36 0.27 0.09 (-0.01, 0.18) [P = 0.0818]
Week 78 0.39 0.29 0.10 (0.00, 0.20) [P = 0.0468]
Week 104 0.38 0.33 0.05 (-0.05, 0.15) [P = 0.3159]
Treatment flexibility score
Baseline [mean (SD)] 4.99 (1.27) 5.01 (1.22)
Change from baselinec
Week 8 0.15 0.25 -0.09 (-0.20, 0.01) [P = 0.0804]
Week 28 0.24 0.22 0.02 (-0.09, 0.13) [P = 0.7172]
Week 52 0.41 0.28 0.13 (0.02, 0.23) [P = 0.0224]
Week 78 0.29 0.25 0.04 (-0.07, 0.15) [P = 0.5156]
Week 104 0.39 0.34 0.05 (-0.06, 0.16) [P = 0.3578]
Satisfaction with understanding diabetes score
Baseline [mean (SD)] 4.91 (1.19) 4.82 (1.16)
Change from baselinec
Week 8 0.27 0.23 0.04 (-0.04, 0.13) [P = 0.3180]
Week 28 0.32 0.29 0.03 (-0.06, 0.12) [P = 0.4947]
Week 52 0.43 0.36 0.07 (-0.02, 0.16) [P = 0.1211]
Week 78 0.44 0.39 0.05 (-0.04, 0.14) [P = 0.2995]
Week 104 0.47 0.47 0.01 (-0.09, 0.10) [P = 0.9114]
Treatment recommendation score
Baseline [mean (SD)] 5.24 (1.19) 5.24 (1.17)
Change from baselinec
Week 8 0.18 0.16 0.03 (-0.06, 0.11) [P = 0.5436]
Week 28 0.24 0.24 0.00 (-0.08, 0.09) [P = 0.9577]
Week 52 0.34 0.25 0.09 (0.00, 0.18) [P = 0.0475]
Week 78 0.33 0.22 0.11 (0.03, 0.20) [P = 0.0113]
Week 104 0.35 0.27 0.07 (-0.02, 0.16) [P = 0.1088]
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difference. However, to our knowledge, no minimally
important threshold has been established for the DTSQs. In
a response written to the United States Food and Drug
Administration, Bradley [19] stated that ‘‘a statistically
significant difference on measures of treatment satisfaction
that have been designed explicitly to measure issues of
importance to patients (e.g., DTSQ) will necessarily be an
important difference.’’
In conclusion, although patients with T2DM treated with
empagliflozin did not show a significant improvement in
Table 4 Mean baseline and adjusted mean change from baseline in perceived hyperglycemia and hypoglycemia
Scale score time point Empagliflozin 25 mg Glimepiride 1–4 mg Treatment difference between empagliflozin
25 mg and glimepiride 1–4 mga
Perceived frequency of hyperglycemia
Baseline [mean (SD)] 2.50 (1.96) 2.46 (1.92)
Change from baselineb
Week 8 -0.90*** -0.77*** -0.13 (-0.30, 0.04) [P = 0.1324]
Week 28 -0.97*** -0.72*** -0.24 (-0.41, -0.07) [P = 0.0056]
Week 52 -1.05*** -0.74*** -0.30 (-0.48, -0.13) [P = 0.0006]
Week 78 -1.08*** -0.71*** -0.37 (-0.55, -0.20) [P\ 0.0001]
Week 104 -0.93*** -0.67*** -0.26 (-0.44, -0.08) [P = 0.0039]
Perceived frequency of hypoglycemia
Baseline [mean (SD)] 0.76 (1.43) 0.85 (1.53)
Change from baselinec
Week 8 0.04 0.17** -0.14 (-0.28, 0.01) [P = 0.0719]
Week 28 -0.12* 0.20*** -0.32 (-0.47, -0.17) [P\ 0.0001]
Week 52 -0.01 0.18*** -0.20 (-0.35, -0.05) [P = 0.0109]
Week 78 -0.10 0.12* -0.22 (-0.37, -0.06) [P = 0.0055]
Week 104 -0.02 0.21*** -0.23 (-0.39, -0.07) [P = 0.0043]
DTSQs Diabetes Treatment Satisfaction Questionnaire, status version, SD standard deviation
* P value\0.05; ** P value\0.01; *** P value\0.001
a Data presented in this column represent difference in adjusted mean changes from baseline, 95 % confidence interval, and P value
b Final adjusted model for change from baseline contained visit, treatment, treatment-by-visit interaction, baseline DTSQs item score, country,
age, baseline diastolic blood pressure, and time since diagnosis of type 2 diabetes mellitus as fixed effects and random intercept by subject
c Final adjusted model for change from baseline contained visit, treatment, treatment-by-visit interaction, baseline DTSQs item score, age,
baseline body mass index, baseline HbA1c (glycated hemoglobin), baseline diastolic blood pressure, and baseline systolic blood pressure as fixed
effects and random intercept by subject
Table 3 continued
Scale score time point Empagliflozin 25 mga Glimepiride 1–4 mga Treatment difference between empagliflozin
25 mg and glimepiride 1–4 mgb
Treatment continuation score
Baseline [mean (SD)] 5.30 (1.09) 5.26 (1.08)
Change from baselinec
Week 8 0.21 0.19 0.02 (-0.06, 0.10) [P = 0.6042]
Week 28 0.22 0.20 0.03 (-0.06, 0.11) [P = 0.5234]
Week 52 0.28 0.20 0.08 (-0.01, 0.16) [P = 0.0787]
Week 78 0.24 0.18 0.06 (-0.03, 0.14) [P = 0.1804]
Week 104 0.27 0.23 0.04 (-0.04, 0.13) [P = 0.3469]
DTSQs Diabetes Treatment Satisfaction Questionnaire, status version, SD standard deviation
a All within-treatment changes from baseline were significant (P\ 0.001)
b Data presented in this column represent difference in adjusted mean changes from baseline, 95 % confidence interval, and P value
c Final adjusted model for change from baseline contained visit, treatment, treatment-by-visit interaction, baseline DTSQs item score, baseline
diastolic blood pressure, and race as fixed effects and random intercept by subject
1206 Qual Life Res (2016) 25:1199–1207
123
DTSQs scale score at 104 weeks compared with patients
treated with glimepiride, a significant benefit in favor of
empagliflozin with regard to perceived hyperglycemia and
perceived hypoglycemia was observed at all visits from
week 28 onward up to the final assessment. This finding is
consistent with the clinical results reported for the EMPA-
REG H2H-SU trial.
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